Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan-Jun;14(1):86-91.
doi: 10.5005/jp-journals-10018-1426.

High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience

Rajesh Upadhyay  1 , Navin K Soni  2 , Ashwin A Kotamkar  3 , Azra Naseem  4 , Aaditi Phadke  3 , Shreshth Nayar  5 , Shailesh Pallewar  3 , Parvan Shetty  3 , Ashish Mungantiwar  6 , Sunil Jaiswal  7 , Amit Qamra  3
Affiliations
Review

High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience

Rajesh Upadhyay et al. Euroasian J Hepatogastroenterol. 2024 Jan-Jun.

Abstract

Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same.

How to cite this article: Upadhyay R, Soni NK, Kotamkar AA, et al. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.

Keywords: Dual-drug release; Gastroesophageal reflux disease; High dose; Pantoprazole; Proton pump inhibitors.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

Figures

Fig. 1
Fig. 1
Pathophysiology of gastroesophageal reflux disease (GERD)
Fig. 2
Fig. 2
Algorithm for management of GERD by Association of Physicians of India-Indian Society of Gastroenterology
Fig. 3
Fig. 3
Illustration of pantoprazole 80 mg dual release gastro-resistant tablets and its plasma profile
See this image and copyright information in PMC

References

    1. Dawoodi S, Dawoodi I, Dixit P. Gastrointestinal problem among Indian adults: Evidence from longitudinal aging study in India 2017–18. Front Public Health. 2022;26(10):911354. doi: 10.3389/fpubh.2022.911354. - DOI - PMC - PubMed
    1. Ami D, Sperber AD, Shrikant I, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi: 10.1053/j.gastro.2020.04.014. - DOI - PubMed
    1. Al Ghadeer HA, Alabbad ZE, AlShaikh SB, et al. Prevalence of gastroesophageal reflux disease and associated risk factors in the Eastern Region, Saudi Arabia. Cureus. 2021;13(11):e19599. doi: 10.7759/cureus.19599. - DOI - PMC - PubMed
    1. Chowdhury SD, George G, Ramakrishna K, et al. Prevalence and factors associated with gastroesophageal reflux disease in southern India: A community-based study. Indian J Gastroenterol. 2019;38(1):77–82. doi: 10.1007/s12664-018-00931-6. - DOI - PubMed
    1. Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40(2):209–219. doi: 10.1007/s12664-020-01104-0. - DOI - PubMed

LinkOut - more resources